Please use this identifier to cite or link to this item:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

New cannabinoid receptor antagonists as pharmacological tool

AuthorsGonzález-Naranjo, Pedro CSIC ORCID; Pérez, Concepción; Girón, Rocío; Sánchez-Robles, E. M.; Martín-Fontelles, M. I.; Carrillo-López, N.; Martín-Vírgala, J.; Naves, M.; Campillo, Nuria E. CSIC ORCID ; Páez, Juan A. CSIC ORCID
KeywordsCannabinoid receptors
Indazole ether
Bone disease
Pharmacological tool
Issue Date2020
CitationBioorganic and Medicinal Chemistry 28(19): 115672 (2020)
AbstractSynthesis and pharmacological evaluation of a new series of cannabinoid receptor antagonists of indazole ether derivatives have been performed. Pharmacological evaluation includes radioligand binding assays with [H]-CP55940 for CB1 and CB2 receptors and functional activity for cannabinoid receptors on isolated tissue. In addition, functional activity of the two synthetic cannabinoids antagonists 18 (PGN36) and 17 (PGN38) were carried out in the osteoblastic cell line MC3T3-E1 that is able to express CB2R upon osteogenic conditions. Both antagonists abolished the increase in collagen type I gene expression by the well-known inducer of bone activity, the HU308 agonist. The results of pharmacological tests have revealed that four of these derivatives behave as CB2R cannabinoid antagonists. In particular, the compounds 17 (PGN38) and 18 (PGN36) highlight as promising candidates as pharmacological tools.
Publisher version (URL)
Identifiersdoi: 10.1016/j.bmc.2020.115672
issn: 0968-0896
Appears in Collections:(IQM) Artículos
(CIB) Artículos
(CIAL) Artículos

Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Google ScholarTM


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.